AGC Biologics has partnered with Takara Bio to collaborate on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine. The vaccine will be developed based on Osaka University and AnGes, Inc.’s expertise of developing plasmid DNA products.

“We are working hard in this fight against COVID-19,” said Takara Bio’s CEO Koichi Nakao. “We are grateful for the support of AGC Biologics. This partnership will help us move safely and quickly in the development of this vaccine.”

“AGC Biologics is delighted to be working with Takara Bio on a project that will make a big difference for countless people,” said AGC Biologics CBO Mark Womack. “Our organization looks forward to partnering with Takara Bio to successfully fight this global threat.”

AGC Biologics has manufacturing facilities in Asia, Europe and the U.S., with experience providing commercial market supply of pDMA for EMA and FDA approvals.